Journal of Tuberculosis and Lung Disease ›› 2020, Vol. 1 ›› Issue (1): 65-70.doi: 10.3969/j.issn.2096-8493.2020.01.014
• Original Articles • Previous Articles Next Articles
WANG Yan, HE Wei, HUANG Tao, WU Gui-hui()
Received:
2020-01-01
Online:
2020-06-30
Published:
2020-07-07
Contact:
WU Gui-hui
E-mail:wghwgh2584@sina.com
WANG Yan, HE Wei, HUANG Tao, WU Gui-hui. Analysis of risk factors of drug-induced liver injury in hospitalized tuberculosis patients complicated with HIV/AIDS co-infection[J]. Journal of Tuberculosis and Lung Disease , 2020, 1(1): 65-70. doi: 10.3969/j.issn.2096-8493.2020.01.014
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.jtbld.cn/EN/10.3969/j.issn.2096-8493.2020.01.014
影响因素 | 肝损伤组(87例) | 无肝损伤组(77例) | χ2值 | P值 |
---|---|---|---|---|
性别 | 0.293 | 0.588 | ||
男 | 76(87.4) | 65(84.4) | ||
女 | 11(12.6) | 12(15.6) | ||
年龄组(岁) | 2.297 | 0.317 | ||
18~ | 48(55.2) | 50(64.9) | ||
45~ | 27(31.0) | 16(20.8) | ||
60~80 | 12(13.8) | 11(14.3) | ||
结核病类型 | 0.119 | 0.942 | ||
肺结核 | 38(43.7) | 35(45.4) | ||
肺外结核 | 5(5.7) | 5(6.5) | ||
肺结核+肺外结核 | 44(50.6) | 37(48.1) | ||
静脉注射毒品史 | 0.040 | 0.842 | ||
有 | 5(5.7) | 5(6.5) | ||
无 | 82(94.3) | 72(93.5) | ||
乙型肝炎病毒抗原阳性 | 0.049 | 0.825 | ||
是 | 17(19.5) | 14(18.2) | ||
否 | 70(80.5) | 63(81.8) | ||
丙型肝炎病毒抗体阳性 | 0.075 | 0.784 | ||
是 | 9(10.3) | 9(11.7) | ||
否 | 78(89.7) | 68(88.3) | ||
CD4+T淋巴细胞计数(个/μl) | 14.880 | 0.005 | ||
0~ | 40(46.0) | 26(33.7) | ||
50~ | 11(12.6) | 15(19.5) | ||
100~ | 13(14.9) | 23(29.9) | ||
200~ | 21(24.1) | 7(9.1) | ||
≥414 | 2(2.4) | 6(7.8) | ||
规范化HAART治疗 | 0.612 | 0.434 | ||
是 | 38(43.7) | 29(37.7) | ||
否 | 49(56.3) | 48(62.3) | ||
抗真菌药品治疗 | 6.848 | 0.009 | ||
是 | 41(47.1) | 21(27.3) | ||
否 | 46(52.9) | 56(72.7) | ||
磺胺类药品治疗 | 0.014 | 0.906 | ||
是 | 29(33.3) | 25(32.5) | ||
否 | 58(66.7) | 52(67.5) |
影响因素 | β值 | Wald χ2值 | P值 | OR(95%CI)值 | |
---|---|---|---|---|---|
常量 | -1.860 | 1.083 | 2.951 | 0.086 | 0.156(0.624~2.810) |
性别 | 0.256 | 0.527 | 0.237 | 0.627 | 1.292(0.460~3.627) |
年龄组(岁) | 0.777 | 0.678 | |||
18~ | -0.109 | 0.517 | 0.045 | 0.832 | 0.896(0.326~2.468) |
45~ | 0.289 | 0.592 | 0.239 | 0.625 | 1.335(0.419~4.260) |
60~80 | - | - | - | - | - |
CD4+T淋巴细胞计数(个/μl) | 14.589 | 0.006 | |||
0~ | 1.406 | 0.934 | 2.269 | 0.132 | 4.080(0.655~5.427) |
50~ | 0.669 | 0.991 | 0.456 | 0.500 | 1.952(0.280~13.603) |
100~ | 0.687 | 0.947 | 0.526 | 0.468 | 1.987(0.311~12.714) |
200~ | 2.592 | 0.996 | 6.769 | 0.009 | 13.357(1.895~94.136) |
≥414 | - | - | - | - | |
使用抗真菌药品 | 1.042 | 0.390 | 7.122 | 0.008 | 2.834(1.319~6.089) |
结核病类型 | 0.857 | 0.651 | |||
肺结核 | -0.178 | 0.398 | 0.200 | 0.655 | 0.837(0.384~1.825) |
肺外结核 | -0.663 | 0.741 | 0.800 | 0.371 | 0.515(0.121~2.202) |
肺结核+肺外结核 | - | - | - | - | |
静脉注射毒品史 | -0.338 | 0.811 | 0.174 | 0.677 | 0.713(0.145~3.495) |
乙型肝炎病毒抗原阳性 | -0.001 | 0.470 | 0.000 | 0.998 | 0.999(0.398~2.510) |
丙型肝炎病毒抗体阳性 | 0.356 | 0.641 | 0.310 | 0.578 | 1.428(0.407~5.012) |
规范化HAART治疗 | 0.314 | 0.395 | 0.632 | 0.427 | 1.369(0.631~2.968) |
磺胺类药品治疗 | 0.281 | 0.384 | 0.537 | 0.464 | 1.325(0.624~2.810) |
[1] | 沈银洲, 卢洪洲. 艾滋病合并结核病诊治现状. 中国实用内科杂志, 2015,35(8):671-674.doi: 10.7504/nk2015070109. |
[2] | World Health Organization. Global tuberculosis report 2019. Geneva:World Health Organization, 2019. |
[3] |
Kullak Ublick GA, Andrade RJ, Merz M, et al. Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut, 2017,66(6):1154-1164. doi: 10.1136/gutjnl-2016-313369.
doi: 10.1136/gutjnl-2016-313369 URL pmid: 28341748 |
[4] | 周林, 陈磊, 赖钰基, 等. TB/HIV双重感染患者抗结核治疗药品不良反应分析. 中国防痨杂志, 2011,33(2):77-81. |
[5] | 中华医学会结核病学分会. 抗结核药物性肝损伤诊治指南(2019年版). 中华结核和呼吸杂志, 2019,42(5):343-356. doi: 10.3760/cma.j.issn.1001-0939.2019.05.007. |
[6] | 中华医学会感染病学分会艾滋病丙型肝炎学组,中国疾病预防控制中心. 中国艾滋病诊治指南(2018版). 中华内科杂志, 2018,57(12):867-884. doi: 10.3760/cma.j.issn.0578-1426.2018.12.002. |
[7] | 中华医学会感染病学分会艾滋病学组,中华医学会热带病与寄生虫学分会艾滋病学组. HIV合并结核分枝杆菌感染诊治专家共识. 中华临床感染病杂志, 2017,10(2):81-90.doi: 10.3760/cma.j.issn.1674-2397.2017.02.001. |
[8] | 中华人民共和国国家卫生和计划生育委员会. WS 288—2017肺结核诊断. 2017-11-09. |
[9] | 中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南(2015年版). 中华肝脏病杂志, 2015,23(11):810-820. doi: 10.3760/cma.j.issn.1007-3418.2015.11.004. |
[10] | 王倪, 刘二勇, 马艳, 等. HIV感染者抗结核预防治疗试点实施及效果分析. 中国艾滋病性病, 2018,24(10):986-989. doi: 10.13419/j.cnki.aids.2018.10.07. |
[11] |
Ngouleun W, Biapa Nya PC, Pieme AC, et al. Risk assessment of hepatotoxicity among tuberculosis and human immunodefificiency virus/AIDS-coinfected patients under tuberculosis treatment. Int J Mycobacteriol, 2016,5(4):482-488. doi: 10.1016/j.ijmyco.2016.05.003.
doi: 10.1016/j.ijmyco.2016.05.003 URL pmid: 27931691 |
[12] |
Alamo ST, Kunutsor S, Walley J, et al. Performance of the new WHO diagnostic algorithm for smear-negative pulmonary tuberculosis in HIV prevalent settings: a multisite study in Uganda. Trop Med Int Health, 2012,17(7):884-895. doi: 10.1111/j.1365-3156.2012.03003.x.
doi: 10.1111/j.1365-3156.2012.03003.x URL |
[13] | 张廷梅, 熊敏, 陈静. 耐多药结核病抗结核治疗依从性与药品不良反应. 贵阳医科大学学报, 2016,41(5):597-599. doi: 10.19367/j.cnki.1000-2707.2016.05.027. |
[14] | 李烨, 何鸿雁, 彭颖, 等. 川南地区HIV/AIDS合并结核感染者在抗结核治疗中肝损伤情况临床分析. 中国临床研究, 2016,29(3):321-323,327. doi: 10.13429/j.cnki.cjcr.2016.03.009. |
[15] | 卜岚, 白轩. HIV/AIDS合并肺结核患者抗结核分枝杆菌治疗肝毒性的危险因素. 中华实验和临床感染病杂志(电子版), 2018,12(2):183-188. doi: 10.3877/cma.j.issn.1674-1358.2018.02.017. |
[16] | 邹俊, 刘燕芬, 吴念宁, 等. HIV/TB 患者抗结核治疗强化期发生肝损伤的危险因素. 中华临床医师杂志(电子版), 2013,7(20):9047-9049. doi: 10.3877/cma.j.issn.1674-0785.2013.20.010. |
[17] | 吴念宁, 陈万, 邹俊, 等. HIV/TB病人抗结核治疗强化期发生药物性肝炎的研究. 中国艾滋病性病, 2014,20(1):13-16. doi: 10.13419/j.cnki.aids.2014.01.008. |
[18] | 唐玉珍, 陈竹, 吴蓓, 等. 169例急性药物性肝损害的临床特征及易感因素分析. 中国肝脏病杂志(电子版), 2014,6(2):31-34. doi: 10.3969/j.issn.1674-7380.2014.02.008. |
[19] |
Hassen Ali A, Belachew T, Yami A, et al. Anti-tuberculosis drug induced hepatotoxicity among TB/HIV co-infected patients at Jimma University Hospital, Ethiopia: nested case-control study. PLoS One, 2013,8(5):e64622. doi: 10.1371/journal.pone.0064622.
doi: 10.1371/journal.pone.0064622 URL pmid: 23696901 |
[20] | 张振宇, 张燕娟, 王姣娇, 等. 抗真菌药品肝毒性及相关临床检验. 中国卫生标准管理, 2018,9(20):92-95. doi: 10.3969/j.issn.1674-9316.2018.20.042. |
[21] | 钟皎, 裴泽军. 唑类抗真菌药物致药物性肝损伤50例分析. 中国药房, 2016,27(11):1496-1499.doi: 10.6039/j.issn.1001-0408.2016.11.18. |
[22] | 吴妙燕, 吕迅羽, 何梅凤. 氟康唑不良反应的文献分析. 中国实用医药, 2011,6(12):34-36.doi: 10.3969/j.issn.1673-7555.2011.12.019. |
[23] | 刘晓东, 于丹, 菅凌燕, 等. 三氮唑类抗真菌药不良反应的文献分析. 中国新药杂志, 2013,22(13):1951-1954. |
[1] | ZHU Guo-feng, LIU Xiao-qing. The new era of systematic immunology of tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2020, 1(3): 195-212. |
[2] | YI Jun-li, YANG Xin-yu, ZHANG Jie, TIAN Li-li, DING Bei-chuan, WU Wen-qing. Application evaluation of three methods for identification between Mycobacterium tuberculosis complex and non-tuberculous mycobacteria [J]. Journal of Tuberculosis and Lung Disease, 2020, 1(3): 240-244. |
[3] | SU Bi-yi, ZHOU De-wang, MA Pin-yun, GUAN Ping, TAN Yao-ju. Diagnostic value of melting curve method in detecting resistance of Mycobacterium tuberculosis to rifampicin and isoniazid [J]. Journal of Tuberculosis and Lung Disease, 2020, 1(3): 245-248. |
[4] | DAI Zhi-song, LIN Shu-fang, WEI Shu-zhen, ZHOU Yin-fa. Analysis of epidemiological characteristics of pulmonary tuberculosis in Fujian Province from 2011 to 2019 [J]. Journal of Tuberculosis and Lung Disease, 2020, 1(3): 249-255. |
[5] | LI Yan-hong, TAO Xue-yong, XIE Ying, WANG Qiao-zhi, CHENG Ling-zhi, TANG Yi, XU Zu-hui, LIU Li-qin, TANG Xi-liang. Comparision of the work quality before and after reformation of tuberculosis control and prevention service system in Hu’nan Province [J]. Journal of Tuberculosis and Lung Disease, 2020, 1(3): 256-261. |
[6] | WANG Mei-hua, ZHANG Wen-qian, JING Rui, ZHANG Guang-li. Analysis of epidemiological characteristics of pulmonary tuberculosis in Ji’nan from 2010 to 2019 [J]. Journal of Tuberculosis and Lung Disease, 2020, 1(3): 262-264. |
[7] | AN Hong-xia, YANG Feng-qin, LU Chuan, MA Xiu-xia. Analysis of the effect of extended nursing service by QQ group on health education for tuberculosis patients [J]. Journal of Tuberculosis and Lung Disease, 2020, 1(3): 265-269. |
[8] | SUN Ming-lei, WU Qun-hong, GUAN Li, ZHAO Juan, WANG Chen, ZOU Dan-dan, LIANG Li-bo. Analysis of situation and influencing factors of patient delay in tuberculosis in tuberculosis patients from Heilongjiang in 2004 [J]. Journal of Tuberculosis and Lung Disease, 2020, 1(3): 270-275. |
[9] | MA Hui-min, ZHANG Li-fan, LIU Xiao-qing. Research progress on the mechanism of latent tuberculosis infection progressing to active tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2020, 1(3): 276-280. |
[10] | WANG Le-le, YANG Song, TANG Shen-jie. Progress on changes of micronutrients and nutritional therapy of active pulmonary tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2020, 1(3): 281-284. |
[11] | MA Yan, YANG Xiao-jun, REN Zhen-juan, SU Yun-kai. Clinical value of Genechip in detecting multidrug-resistant Mycobacterium tuberculosis bacteria in sputum samples [J]. Journal of Tuberculosis and Lung Disease, 2020, 1(2): 112-116. |
[12] | REN Zhen-juan, ZHANG Hai-jie, SU Yun-kai, MA Yan, LIU Yao. Correlation between amikacin resistance and rrs gene mutation in multidrug-resistant Mycobacterium tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2020, 1(2): 117-120. |
[13] | TANG Gui-hua, SUN Qian, WANG Xiao-fan, XIAN Hai-bin, ZHANG Qian, YANG Xiao-wei, WANG Li. The value of GeneXpert MTB/RIF technology in tuberculosis detection and resistance to rifampin [J]. Journal of Tuberculosis and Lung Disease, 2020, 1(2): 121-125. |
[14] | WANG Ying, CAI Chun-kui, XU Yan, SUN Shi-xue, LI Gang, GU Xiao-feng, YU Yang. Efficacy analysis of linezolid in the treatment of XDR-PTB [J]. Journal of Tuberculosis and Lung Disease, 2020, 1(2): 136-139. |
[15] | YU Yan-yan, CHEN Zhen-hua, WANG Jue, LYU Yan, CHEN Zhong-nan, LIU Bin-bin, YI Song-lin, HU Pei-lei, TAN Yun-hong. Clinical characteristics and influencing factors of culture-positive pulmonary tuberculosis patients coinfected with non-tuberculous mycobacteria [J]. Journal of Tuberculosis and Lung Disease, 2020, 1(2): 144-148. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||